Detalhe da pesquisa
1.
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(10): 1094-1108, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37714168
2.
Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
Crit Rev Clin Lab Sci
; : 1-27, 2023 Oct 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37882463
3.
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 382(22): 2091-2102, 2020 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32343890
4.
Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome.
Cancer Immunol Immunother
; 72(1): 137-149, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35771253
5.
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies.
Eur J Nucl Med Mol Imaging
; 50(7): 1906-1918, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36813980
6.
Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer.
Int J Mol Sci
; 24(10)2023 May 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37240349
7.
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
Br J Cancer
; 126(6): 907-916, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34912074
8.
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.
Oncologist
; 27(10): e783-e795, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36124924
9.
Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome.
Eur J Nucl Med Mol Imaging
; 49(2): 460-469, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34218300
10.
[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment.
Eur J Nucl Med Mol Imaging
; 49(4): 1101-1112, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34623453
11.
Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer.
BJU Int
; 130(2): 217-225, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34741789
12.
The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer.
Br J Clin Pharmacol
; 88(3): 1170-1178, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34436788
13.
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Lancet Oncol
; 22(9): 1250-1264, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34388386
14.
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
Int J Cancer
; 148(2): 385-395, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32965028
15.
Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Oncologist
; 26(8): e1347-e1358, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33111480
16.
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.
Eur J Nucl Med Mol Imaging
; 48(10): 3325-3334, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33686456
17.
Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study.
Clin Chem
; 66(6): 842-851, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32408351
18.
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
BMC Cancer
; 20(1): 884, 2020 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32928177
19.
A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer.
Br J Clin Pharmacol
; 84(5): 1064-1067, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29384591
20.
Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.
Br J Clin Pharmacol
; 84(1): 122-129, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28881501